LUMIBIRD strengthens its position in strategic laser technologies

· Sale of Lumibird’s stake in Cilas

· Long-term industrial partnership with Cilas

· Lumibird takes over Laser MégaJoule’s maintenance operations

Against a backdrop of accelerating defense investment in Europe and a growing need for technological sovereignty, Lumibird continues to implement its strategy aimed at strengthening its position in critical laser technologies for the Defense, Aerospace, Research, and Industrial markets.

The Group today announces the signing of a comprehensive agreement with Cilas and its shareholders, marking a new step in this strategy. The plan outlined in this agreement would provide lasting clarity regarding the industrial positioning of the various players in the French laser sector while strengthening long-term technological cooperation.

👉 Read our press release: https://www.lumibird.com/wp-content/uploads/260724Lumibird_Cilas_EN.pdf

Lumibird enters into exclusive negociations for the sale of its medical division to IPG Photonics Corporation

July 16, 2026

A defining milestone in Lumibird’s development, creating two focused leaders for the next stage of their growth.

Following receipt of a binding offer, Lumibird Group announces today that it has entered into exclusive negotiations for the sale of its Medical Division to IPG Photonics Corporation, for an enterprise value of €300 million, which may be increased by an earn-out of up to €50 million based on future performance in 2026 and 2027.

More than a portfolio transaction, this proposed transaction would represent a defining milestone in Lumibird’s history.

👉 Read our press release: : https://www.lumibird.com/wp-content/uploads/260716_LUMIBIRD_MEDICAL_EN.pdf